ASHISH LIFE SCIENCES PVT LTD WALK IN INTERVIEW ON 30th,JULY AND 31st,JULY, 2021 @ AMBERNATH

ABOUT COMPANY :

Ashish Life Science is established in 2002 and is dedicated to Veterinary science.

We believe animals have been catering to service of mankind and it is our duty to reciprocate back.

Our manufacturing is carried out in world class facilities i which is dedicated to Veterinary products and currently exporting to over 60 countries all over the world.

Our World-class facility at Tarapur, Maharashtra, India, having approvals of WHO GMP, EU GMP and APVMA for manufacturing of various Veterinary dosage forms. Located at one of the most thriving industrial hubs, the plant is equipped with the latest technology and infrastructure

For more updates follow 

www.globalpharmanews.co.in

To get global pharma news updates in whatsapp please 

CLICK HERE

TEENA BIO LABS PVT LTD HIRING FRESHERS & EXPERIENCE CANDIDATES FOR QC DEPARTMENT @ HYDERABAD

ABOUT COMPANY :

TEENA BIOLABS PVT LTD is a Govt. approved contract testing laboratory with more than a decade of experience, providing high quality laboratory services under one roof in the field of Chemical, Instrumental, Biological and Microbiological services. Our 15,000 sq. ft. facility located in Hyderabad, India practicing cGLP standards is home to an extensive array of instrumentation and professional staff all dedicated to serving more than 200 clients.

Teena Biolabs possesses a strong analytical capability in Method development & validation (HPLC/GC/UV/PSD/ICP...), Extractable & Leachable(E/L) studies (LC-MS/GC-MS/,ICP-MS), Physical characterization studies (XRD/DSC/TGA), Trace metal Analysis(ICP-MS/ICP-OES), Residual Genotoxic impurity studies (GC-MS/LC_MS), Stability/Photo stability studies and Pre clinical studies etc.

VACANCY DETAILS :

COMPANY : Teena bio labs Pvt Ltd 

EXPERIENCE : 0-5 years experience in  Ion chromatography instrument experience.

POSTS : 5

please call  9849540844 / 9703015751 ,

please share your resume to ic@teenalabs.com

For more updates follow 

www.globalpharmanews.co.in

To get global pharma news updates in whatsapp please 

CLICK HERE

ZUVENTUS HEALTHCARE LTD (Emcure Group) HIRING FRESHERS FOR QC DEPARTMENT @ BANGALORE

ABOUT COMPANY :

Emcure Pharmaceuticals Ltd. was incorporated on 16th April, 1981. The Group has emerged as significant force in manufacturing and marketing both in India and Globally.

The core strength lies in developing and manufacturing differentiated pharmaceutical products in – house and commercializing the same through marketing infrastructure across the geographies.

The group is ranked as the 12th largest Pharmaceutical company (source: AIOCD-AWACS MAT MAR 19) in India.

The Group has emerged as a leader in various therapy segments like Cardiology, Pain and Analgesics, HIV, Gynecology, Nephrology, Cephalosporin Injectable, Hepatology, Oncology, Diabetology, Vitamins – Minerals & Nutrients as well as Blood products.

The group has gained significant advantage due to its diversified / specialized group companies like Zuventus, Gennova and Heritage. Headed by a professional team each of this group has utilized their own strengths across therapy segments and geographies and know-how to make the group stronger and well entrenched.

The group products are available globally over 65 countries and enjoy the alliance of local and multinational companies to attain leadership.

The group has subsidiaries in Dubai, Brazil, South Africa, Singapore and Nigeria and branch offices in Russia, Morocco and Shanghai.

The group has nine manufacturing facilities including eight in India and one in United States, five of which are approved by USFDA.

Our quality is respected in India and world over and is testimonial of our supplies to leading multinationals.

Our group is respected as a reliable and proven co- marketing partner, evident through our collaborative relationship with companies like Sanofi, Roche, B.M.S etc.

We offer technological expertise across various areas like API’s (First to market opportunities in domestic markets), Bio Similars, Novel Drug Delivery Systems, Paragraph IV opportunities in US, wide expertise with various dosage forms, Chiral molecules, Peptides, Polymer based chemistry & complex products.

Through Zuventus the group has emerged as a leader in Acute & Semi Chronic therapies in Indian Pharmaceutical Market. For further info click and access www.emcure.co.in

For more updates follow 

www.globalpharmanews.co.in

To get global pharma news updates in whatsapp please 

CLICK HERE

SUNRISE INTERNATIONAL LABS LTD HIRING FRESHERS & EXPERIENCE CANDIDATES FOR QC /PRODUCTION & QA DEPARTMENTS @ HYDERABAD

ABOUT COMPANY :

Established in 1986 in Cherlapally, Hyderabad India, Sunrise International Labs Ltd., which is now a subsidiary of Perdaman Pharmaceuticals Pvt Ltd has been supplying the domestic Indian market and international market with branded and generic pharmaceutical formulations for over 25 years. Sunrise has also been involved in providing contract manufacturing for many national and multinational companies.

Covering a wide range of therapeutic segments , Sunrise is also well known for its expertise in pelletisation and delivery of drug development systems.

Sunrise is a WHO, cGMP certified facility with in-house testing facilities, as well as a water treatment plant and well equipped Quality Control, manufacturing , administration and storage departments.

VACANCY DETAILS :

Sunrise International Labs Ltd, one of the pharmaceutical companies in india is inviting applicants for some of their roles for Formulation plant at Hyderabad.

U

1. Jr. Executive-Qc: B.Pharm/M.Pharm - 0 - 1 year

2. Jr. Executive-IPQA: B.Pharm/M.Pharm - 0-1 year

3. Trainee - Production: B.Sc/M.Sc, Fresher.

Please share your updated profile with current and expected compensation at hr@sunriseintlabs.com

For more updates follow 

www.globalpharmanews.co.in

To get global pharma news updates in whatsapp please 

CLICK HERE

HONOUR LABS LTD WALK IN INTERVIEW FOR FRESHERS & EXPERIENCE CANDIDATES ON 25 th, JULY, 2021 @ HYDERABAD

About Company :

Established in 2012, Honour Lab Limited is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs) & Intermediates. Honour Lab Limited has 5 state-of-the-art manufacturing facilities located in Hyderabad, Visakhapatnam and Pune which are approved by USFDA, TGA, MFDS, MOT, PMDA and PICS.
Backed by a strong R&D with 100+ top notch scientists, the company excels at developing high-quality products which meet the demands of the rapidly growing global drug markets. The company is recognized for its sophisticated manufacturing infrastructure, advanced quality control systems, extensive market insights, in-depth R&D expertise and exemplary customer care.

For more updates follow 

www.globalpharmanews.co.in

To get global pharma news updates in whatsapp please 

CLICK HERE

HETERO LABS LTD WALK IN INTERVIEW FOR FRESHERS ON 25 th, JULY, 2021 @ HYDERABAD

ABOUT COMPANY :

Hetero is a globally renowned vertically integrated pharmaceutical player engaged in research and development, manufacturing, and marketing of high-quality chemical and biologic medicines across diverse therapeutic areas. Backed by 27+ years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, Global Generics, Biosimilars and Custom Pharmaceutical Services. The company is among the largest producers of Active Pharmaceutical Ingredients (APIs) in the world.

Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide, which has been approved by top pharma regulatory bodies of the world. Our portfolio includes 300+ products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology etc. Hetero has a strong global presence in over 126 countries and focusses on making affordable medicines accessible to patients worldwide.

Over the years, Hetero has established its strong leadership in ARVs and Antiviral therapies and caters to 40% of existing global demand for Anti-Retroviral (ARV) APIs and Finished Dosage Forms (FDFs) used in HIV/AIDS treatment.

A track record of responding to Global Public Health Emergencies

The highlight of Hetero’s 27+ years of existence has been its responsive actions to mitigate pandemics and life-threatening diseases afflicting communities across the world. By partnering with innovators for developing Oseltamivir to fight against Swine Flu Pandemic to enabling access to affordable Hepatitis C medicines in underdeveloped countries, Hetero has always endeavoured to do its bit at times of global health crises and save precious lives.

Since the onset of the Covid-19 pandemic, Hetero has been proactive in responding to the various challenges surrounding it. It has been the first company to launch the licensed version of generic Remdesivir under the brand name ‘Covifor’ in India for treating severely infected patients and followed it up with Favipiravir (Favivir) to provide succor to those affected by mild and moderate symptoms. As of today, the company is among the largest manufacturers of Remdesivir globally.

Illustrating its continuing commitment to play its part in the global fight against the pandemic, Hetero has entered into an agreement with the Russian Direct Investment Fund (RDIF) as a manufacturing partner for producing 100 million doses of the Sputnik V vaccine per year. This development also showcases Hetero’s enduring spirit of collaboration and penchant for contributing to global health and well-being.

For more updates follow 

www.globalpharmanews.co.in

To get global pharma news updates in whatsapp please 

CLICK HERE

ARAGEN LIFE SCIENCES (GVK BIO COMPANY) HIRING FRESHERS FOR R& D DEPARTMENT @ BANGALORE

ABOUT COMPANY :

Aragen is a trusted R&D and manufacturing partner to the global life sciences industry. From concept to commercial, we transform your ideas into solutions for better health.

Whether large pharma or biotech, an agrochemical or animal health company, we provide you global resources and proven capabilities at every stage of the biopharma lifecycle, in small and large molecules. Our ability to offer end-to-end solutions or support standalone programs is underpinned by an innovation mindset, enabling technologies, and a partnership approach to every engagement.

At Aragen, we recognize your work is vital, urgent and impacts lives. Our purpose, ‘In every molecule is the possibility for better health’ motivates us to drive the success of your programs, so that we can together transform hope into health for millions of people around the world.

The Year 2021 is a defining milestone on our journey so far. It marks the 20th anniversary of GVK BIO’s resilient growth story and its transformation into Aragen, a trusted R&D and manufacturing partner to the global life sciences industry. With Aragen, we unveil a new brand identity, an inspiring purpose, and a promise to customers

Hi All,

Greetings from Aragen Life Sciences...!!!

(a GVK Bio Company)

We are looking for Fresher candidates for our R&D center located at Bangalore.

Department: Chemistry R&D

Qualification: PhD Freshers (Organic chemistry/Medicinal chemistry/Synthetic chemistry)

Location: Bangalore, Karnataka

Roles: Sr.Research Associate/Associate Scientist.

Interested candidates can share their profiles to raghuveera.vutla.c@aragen.com

Note: Immediate Joinees Preferred

For more updates follow 

www.globalpharmanews.co.in

To get global pharma news updates in whatsapp please 

CLICK HERE

MSN LABORATORIES PVT LTD WALK IN DRIVE FOR FRESHERS & EXPERIENCE ON 23 rd, JULY, 2021 @ HYDERABAD

ABOUT COMPANY :

MSN Group is the fastest growing research-based pharmaceutical company based out of India. Founded in 2003 with a mission to make health care affordable, this Hyderabad-based venture has nine API and five finished dosage facilities established across Hyderabad, USA and Myanmar.

The group has an integrated R&D center for both API and formulation under one roof, dedicated to research and development of pharmaceuticals to make them more accessible. With core focus on speed and consistency in delivery, MSN has achieved the following:

·         More than 650 national and international patents

·         Product portfolio featuring over 350 + APIs

·         250+ Formulations, covering over 35 major therapies

·         Won the trust of more than 40,000,000 customers across 65 countries globally

Innovation and speed form the crux of our business strategy. Backed by a dedicated and experienced team of over 11,000 the organizational environment at MSN integrates multiple disciplines and functions by effective implementation of goals and objectives through technology, coupled with Integrity, Imagination and Innovation.

 Proactive marketing, robust IP strategy, innovative R&D expertise, dynamic SCM, Insight driven IT and World class facilities are our ingredients to success.

In a short span of 17 years, we achieved a record growth of 100% from USD 22 million in 2005 to USD 500 million in 2019. Outstanding workforce, cutting-edge science, state-of-the-art technology and knowledge-intensive initiatives - our work involves creating innovative solutions for tomorrow's healthcare requirements.

For more updates follow 

www.globalpharmanews.co.in

To get global pharma news updates in whatsapp please 

CLICK HERE

MSN LABORATORIES PVT LTD WALK IN DRIVE FOR FRESHERS & EXPERIENCE ON 22 nd, JULY, 2021 @ HYDERABAD

ABOUT COMPANY :

MSN Group is the fastest growing research-based pharmaceutical company based out of India. Founded in 2003 with a mission to make health care affordable, this Hyderabad-based venture has nine API and five finished dosage facilities established across Hyderabad, USA and Myanmar.

The group has an integrated R&D center for both API and formulation under one roof, dedicated to research and development of pharmaceuticals to make them more accessible. With core focus on speed and consistency in delivery, MSN has achieved the following:

·         More than 650 national and international patents

·         Product portfolio featuring over 350 + APIs

·         250+ Formulations, covering over 35 major therapies

·         Won the trust of more than 40,000,000 customers across 65 countries globally

Innovation and speed form the crux of our business strategy. Backed by a dedicated and experienced team of over 11,000 the organizational environment at MSN integrates multiple disciplines and functions by effective implementation of goals and objectives through technology, coupled with Integrity, Imagination and Innovation.

 Proactive marketing, robust IP strategy, innovative R&D expertise, dynamic SCM, Insight driven IT and World class facilities are our ingredients to success.

In a short span of 17 years, we achieved a record growth of 100% from USD 22 million in 2005 to USD 500 million in 2019. Outstanding workforce, cutting-edge science, state-of-the-art technology and knowledge-intensive initiatives - our work involves creating innovative solutions for tomorrow's healthcare requirements.

For more updates follow 

www.globalpharmanews.co.in

To get global pharma news updates in whatsapp please 

CLICK HERE

HETERO LABS LTD WALK IN INTERVIEW FOR FRESHERS FROM 26 th, JULY, TO 30 th, JULY, 2021 @ PALAKOL / BHIMAVARM / PENUGONDA / TADEPALLIGUDAM / ELURU

ABOUT COMPANY :

Hetero is a globally renowned vertically integrated pharmaceutical player engaged in research and development, manufacturing, and marketing of high-quality chemical and biologic medicines across diverse therapeutic areas. Backed by 27+ years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, Global Generics, Biosimilars and Custom Pharmaceutical Services. The company is among the largest producers of Active Pharmaceutical Ingredients (APIs) in the world.

Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide, which has been approved by top pharma regulatory bodies of the world. Our portfolio includes 300+ products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology etc. Hetero has a strong global presence in over 126 countries and focusses on making affordable medicines accessible to patients worldwide.

Over the years, Hetero has established its strong leadership in ARVs and Antiviral therapies and caters to 40% of existing global demand for Anti-Retroviral (ARV) APIs and Finished Dosage Forms (FDFs) used in HIV/AIDS treatment.

A track record of responding to Global Public Health Emergencies

The highlight of Hetero’s 27+ years of existence has been its responsive actions to mitigate pandemics and life-threatening diseases afflicting communities across the world. By partnering with innovators for developing Oseltamivir to fight against Swine Flu Pandemic to enabling access to affordable Hepatitis C medicines in underdeveloped countries, Hetero has always endeavoured to do its bit at times of global health crises and save precious lives.

Since the onset of the Covid-19 pandemic, Hetero has been proactive in responding to the various challenges surrounding it. It has been the first company to launch the licensed version of generic Remdesivir under the brand name ‘Covifor’ in India for treating severely infected patients and followed it up with Favipiravir (Favivir) to provide succor to those affected by mild and moderate symptoms. As of today, the company is among the largest manufacturers of Remdesivir globally.

Illustrating its continuing commitment to play its part in the global fight against the pandemic, Hetero has entered into an agreement with the Russian Direct Investment Fund (RDIF) as a manufacturing partner for producing 100 million doses of the Sputnik V vaccine per year. This development also showcases Hetero’s enduring spirit of collaboration and penchant for contributing to global health and well-being.

For more updates follow 

www.globalpharmanews.co.in

To get global pharma news updates in WhatsApp please 

CLICK HERE

ZYDUS CADILA HEALTH CARE LTD HIRING FRESHERS (B.PHARM / B.Sc / ITI/ DIPLOMA) @ AHMEDABAD PLANT

ABOUT COMPANY : 

Zydus Cadila, a leading Indian Pharmaceutical company is a fully integrated, global healthcare provider. With in-depth domain expertise in the field of healthcare, it has strong capabilities across the spectrum of the pharmaceutical value chain. From formulations to active pharmaceutical ingredients and animal healthcare products to wellness products, Zydus has earned a reputation amongst Indian pharmaceutical companies for providing comprehensive and complete healthcare solutions.

One of the salient features of Zydus is its rich history and lineage. The origin of the company dates all the way back to the 1950s. The company was founded in the year 1952 by Mr. Ramanbhai B. Patel (late), a first-generation entrepreneur and a doyen in the field of Indian Pharmaceuticals.

In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 15,000 crores in FY-21.

Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe.

For more updates follow 

www.globalpharmanews.co.in

To get global pharma news updates in whatsapp please 

CLICK HERE

GRANULES INDIA LTD WALK IN INTERVIEW FOR FRESHERS ON 20 th, JULY, 2021 @ HYDERABAD

ABOUT COMPANY :

Granules India Ltd. is a vertically integrated pharmaceutical company, headquartered in Hyderabad, India. We manufacture Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs), distributed to quality conscious customers in both regulated and semi-regulated markets. We are dedicated to excellence in manufacturing, quality and customer service.

As Granules stands today, our business is bucketed into three areas; the Core business which comprises our ‘core molecules- Paracetamol, Ibuprofen, Metformin, Guaifenesin and Methocarbamol; the Emerging business that focuses on manufacturing APIs with a focus on vertical integration.

For more updates follow 

www.globalpharmanews.co.in

Thank you for visiting my website, Visit again for 

latest pharma updates

AURORE LIFE SCIENCES WALK IN INTERVIEW FOR FRESHERS ON 20 th, JULY, 2021 @ HYDERABAD

ABOUT COMPANY :

Established in 2017, We are a pure-play Active Pharmaceutical Ingredient (API) company keen on delivering superior products in a regulatory compliant environment.

We are backed up with manufacturing facilities in India with a combined manufacturing capacity of 600 KL and our flagship facility in Hyderabad in approved with USFDA, EDQM, WHO Geneva, COFEPRIS, KFDA amongst other regulatory agencies. Our facilities, coupled with a dedicated R&D setup, complement our strategy to be a fully integrated API company with complete control of key starting materials, advanced intermediates and high-quality final product.

With a strong team of R&D experts that complements our strategy, Aurore is rapidly emerging as the most preferred API and key API intermediates supply partner for leading global pharmaceutical companies.

With a robust portfolio of niche and differentiated molecule spread across major therapeutic divisions, we are rapidly establishing ourselves as a reliable partner to serve unmet demands of the market.

 

Aurore Life Sciences is a pure-play API manufacturer with a diverse portfolio of capabilities in delivering efficiencies to generic players globally. Founded in 2017 by a team with vast experience across the pharmaceutical value chain, the company is on a mission to become the most preferred partner for pharmaceuticals.

At Aurore, we aim to push the boundaries to manufacture and deliver high quality products that can be relied upon by both customers and regulators. Our thrust on rapidly adding capabilities have led us to acquire, integrate and expand our reach across the geographies.

For more updates follow 

www.globalpharmanews.co.in

Thank you for visiting my website, Visit again for 

latest pharma updates

HETERO LABS LTD WALK IN INTERVIEW FOR FRESHERS ON 20 th, JULY, 2021 @ VIZAG

ABOUT COMPANY :

Hetero is a globally renowned vertically integrated pharmaceutical player engaged in research and development, manufacturing, and marketing of high-quality chemical and biologic medicines across diverse therapeutic areas. Backed by 27+ years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, Global Generics, Biosimilars and Custom Pharmaceutical Services. The company is among the largest producers of Active Pharmaceutical Ingredients (APIs) in the world.

Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide, which has been approved by top pharma regulatory bodies of the world. Our portfolio includes 300+ products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology etc. Hetero has a strong global presence in over 126 countries and focusses on making affordable medicines accessible to patients worldwide.

Over the years, Hetero has established its strong leadership in ARVs and Antiviral therapies and caters to 40% of existing global demand for Anti-Retroviral (ARV) APIs and Finished Dosage Forms (FDFs) used in HIV/AIDS treatment.

A track record of responding to Global Public Health Emergencies

The highlight of Hetero’s 27+ years of existence has been its responsive actions to mitigate pandemics and life-threatening diseases afflicting communities across the world. By partnering with innovators for developing Oseltamivir to fight against Swine Flu Pandemic to enabling access to affordable Hepatitis C medicines in underdeveloped countries, Hetero has always endeavoured to do its bit at times of global health crises and save precious lives.

Since the onset of the Covid-19 pandemic, Hetero has been proactive in responding to the various challenges surrounding it. It has been the first company to launch the licensed version of generic Remdesivir under the brand name ‘Covifor’ in India for treating severely infected patients and followed it up with Favipiravir (Favivir) to provide succor to those affected by mild and moderate symptoms. As of today, the company is among the largest manufacturers of Remdesivir globally.

Illustrating its continuing commitment to play its part in the global fight against the pandemic, Hetero has entered into an agreement with the Russian Direct Investment Fund (RDIF) as a manufacturing partner for producing 100 million doses of the Sputnik V vaccine per year. This development also showcases Hetero’s enduring spirit of collaboration and penchant for contributing to global health and well-being.

For more updates follow 

www.globalpharmanews.co.in

Thank you for visiting my website, Visit again for 

latest pharma updates

ANTHEM BIOSCIENCES WALK IN INTERVIEW FOR FRESHERS & EXPERIENCE CANDIDATES ON 07 th, AUGUST , 2021 @ MYSURU , KARNATAKA

ABOUT COMPANY :

Anthem Biosciences is a Contract Research and Innovation Service Provider (CRISP), with a built-up capacity to house over 1000 researchers and manufacture novel commercial drug actives, from its two sites in Bangalore, India.

Over its short history, since commencing operations in 2007, the company has become a powerhouse for drug and new products development and manufacture, with equal emphasis on biological and chemistry based products and services.

A team of experienced chemists, biologists and engineers own the responsibility of transparent and ethical dealing with customers. Anthem’s labs have helped new and established biotechs and big pharma, develop, optimize and test proteins, monoclonal antibodies, peptides, large molecules, small molecules, toxins and much more.

In addition to product research and development, Anthem helps test drugs for safety, efficacy (in vitro and in vivo), pre-clinical animal studies in a GLP facility, clone development, Antibody Drug Conjugates, R&D and manufacture of highly potent compounds, flow chemistry based production and large scale commercial product manufacture. Anthem has been successfully inspected by USFDA, PMDA (Japan), EU QPs.

Anthem has leveraged its core competency in organic synthesis to develop new and challenging nutritional products with a strong scientific rationale. These are now being sold globally to nutraceutical and wellness product companies.

Anthem backs up its top flight R&D capabilities with one of the best in class Quality Control and Analytical development capabilities. In addition to optimizing manufacturing schemes, Anthem has helped its clients develop GMP analytical testing methods, characterization and testing, reference standards preparation, stability studies and much more for impurities, intermediates and products. Regulatory compliance, Quality Assurance and CMC documentation experts assist clients bring research products to market.

With its second to none infrastructure Anthem Biosciences can do GMP synthesis ranging from milligram to kilogram, multi-kilogram to multiple ton scale. Apart from modern well equipped labs, the company has a cGMP kilo lab and a versatile GMP pilot plant.

For more updates follow 

www.globalpharmanews.co.in

Thank you for visiting my website, Visit again for 

latest pharma updates

MAITHRI DRUGS PVT LTD WALK IN DRIVE FOR FRESHERS AND EXPERIENCE CANDIDATES ON 17 th JULY, 2021 @ HYDERABAD

Maithri Drugs Private Limited, Bonthapally: Production Department walk-in drive on 17/07/2021

ABOUT COMPANY :

Maithri Drugs is one of India's fast-growing pharmaceutical companies. Maithri's strategic focus is on active pharma ingredients (APIs). The company is widely recognized for its excellent research & development and aggressive growth strategies. Our 30 US DMFs and 9 CEPs in a short span attest to our R&D excellence.

Maithri's manufacturing facility is located in Hyderabad. This facility is audited and approved by the US FDA. In addition, our facility is certified according to the standards of  DCGI, WHO GMP, and ISO 9001:2015 We have a portfolio of 65 products and are continually expanding. Our products cover a broad range of therapeutic categories including CNS, anti-anaemics, anti-bacterial, anti-diabetic, anti-fungal, anti-hyperthyroidism, anti-inflammatory, anti-viral, antihypertensive, cardiovascular, etc. 

Maithri Drugs serves hundreds of customers spread across 35 countries. We have a constant goal of producing high-quality products and providing unparalleled customer service.

WALK IN DETAILS :

Maithri Drugs Private Limited, Bonthapally: Production Department walk-in drive on 17/07/2021

VACANCIES: Trainee's (Fresher's)/ Junior Executive's/ Executive's

QUALIFICATION: B.Sc

ELIGIBILITY CRITERIA: 0-6 yrs of work experience - Only MEN candidates

JOB REQUIREMENTS:

1. Need to have sound knowledge in GMP Document Writing
2. Need to perform QC Sampling, Utility operations, CF operations, Additions and Filtrations.
3. Need to do Batch Charging, Work up, Dryers Monitoring, Receivers Unloading, Equipment Cleaning, Labeling of Drums.

DOCUMENTS TO BE CARRIED: Candidates are requested to carry updated resume, photocopies of educational certificates, latest increment letter, last 3 months pay slips, last 6 months bank statement and photocopy of aadhar card.

TIMINGS: Only MEN candidates may walk-in from 09:00 AM to 01:00 PM

INTERVIEW VENUE & WORK LOCATION: Maithri Drugs Pvt Ltd, Bonthapally, Landmark: Lane Beside Bharat Petroleum Bunk, Bonthapally

For more updates follow 

www.globalpharmanews.co.in

Thank you for visiting my website, Visit again for 

                                      latest pharma updates